Lotronex and the FDA: a fatal erosion of integrity

被引:56
作者
Horton, R [1 ]
机构
[1] Lancet, London WC1X 8RR, England
关键词
D O I
10.1016/S0140-6736(00)04776-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1544 / 1545
页数:2
相关论文
共 3 条
[1]   Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial [J].
Camilleri, M ;
Northcutt, AR ;
Kong, S ;
Dukes, GE ;
McSorley, D ;
Mangel, AW .
LANCET, 2000, 355 (9209) :1035-1040
[2]   Irritable bowel syndrome - New agents targeting serotonin receptor subtypes [J].
De Ponti, F ;
Tonini, M .
DRUGS, 2001, 61 (03) :317-332
[3]  
McColl KEL, 2000, LANCET, V356, P164, DOI 10.1016/S0140-6736(05)73177-9